| pubmed-article:8517711 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8517711 | lifeskim:mentions | umls-concept:C0040300 | lld:lifeskim |
| pubmed-article:8517711 | lifeskim:mentions | umls-concept:C0001428 | lld:lifeskim |
| pubmed-article:8517711 | lifeskim:mentions | umls-concept:C0040421 | lld:lifeskim |
| pubmed-article:8517711 | lifeskim:mentions | umls-concept:C0053882 | lld:lifeskim |
| pubmed-article:8517711 | lifeskim:mentions | umls-concept:C0205321 | lld:lifeskim |
| pubmed-article:8517711 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8517711 | pubmed:dateCreated | 1993-7-22 | lld:pubmed |
| pubmed-article:8517711 | pubmed:abstractText | Penetration of cefprozil into tonsillar and/or adenoidal tissues was investigated for patients undergoing tonsillectomy and/or adenoidectomy. A total of 29 patients ranging in age from 2 to 14 years participated in the study. The tonsils and/or the adenoids were removed at times ranging from 0.33 to 3.17 h after oral administration of a dose of either 7.5 or 20 mg/kg of body weight. A blood sample was also collected as soon as the tissue sample was removed. Plasma, tonsil, and adenoid samples were analyzed for cis and trans isomers of cefprozil by high-performance liquid chromatographic assays. The concentrations of the cis isomer of cefprozil in plasma ranged from 0.60 to 9.87 micrograms/ml at the 7.5-mg/kg dose level and from 1.04 to 20.40 micrograms/ml at the 20-mg/kg dose level. The corresponding concentrations of the cis isomer in tonsil tissue ranged from 0.48 to 2.42 micrograms/g and from 1.00 to 4.29 micrograms/g, respectively. The corresponding concentrations of the cis isomer in adenoid tissue ranged from 0.40 to 4.20 micrograms/g and from 1.74 to 4.94 micrograms/g, respectively. The concentrations of the trans isomer were about 1/10 of those observed for the cis isomer. The median ratios of the cefprozil concentration in tonsillar tissue to that in plasma were 0.37 and 0.47 for patients receiving a 7.5- or a 20-mg/kg oral dose of cefprozil, respectively. The corresponding median ratios for the adenoidal tissue were 0.46 and 0.82, respectively. The cefprozil concentrations in either the tonsillar or the adenoidal tissue at both dose levels over 3.17 h after dosing are much higher than the MICs for common pathogens which cause pharyngitis or tonsillitis. | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8517711 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8517711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8517711 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8517711 | pubmed:month | May | lld:pubmed |
| pubmed-article:8517711 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:8517711 | pubmed:author | pubmed-author:BarbhaiyaR... | lld:pubmed |
| pubmed-article:8517711 | pubmed:author | pubmed-author:CampbellD ADA | lld:pubmed |
| pubmed-article:8517711 | pubmed:author | pubmed-author:WilberR BRB | lld:pubmed |
| pubmed-article:8517711 | pubmed:author | pubmed-author:ReillyJJ | lld:pubmed |
| pubmed-article:8517711 | pubmed:author | pubmed-author:ShyuW CWC | lld:pubmed |
| pubmed-article:8517711 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8517711 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:8517711 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8517711 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8517711 | pubmed:pagination | 1180-3 | lld:pubmed |
| pubmed-article:8517711 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:meshHeading | pubmed-meshheading:8517711-... | lld:pubmed |
| pubmed-article:8517711 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8517711 | pubmed:articleTitle | Penetration of cefprozil into tonsillar and adenoidal tissues. | lld:pubmed |
| pubmed-article:8517711 | pubmed:affiliation | Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Syracuse, New York 13221-4755. | lld:pubmed |
| pubmed-article:8517711 | pubmed:publicationType | Journal Article | lld:pubmed |
